Journal
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
Volume 36, Issue 5, Pages -Publisher
WILEY
DOI: 10.1002/jbt.23023
Keywords
breast cancer; CASC15; MEF2D; miR-654-5p; stemness
Categories
Ask authors/readers for more resources
The long noncoding RNA CASC15 has been found to have prognostic and diagnostic potential for cancer progression and tumorigenesis. This study uncovers the role of CASC15 in regulating the stemness of breast cancer stem cells (BCSCs) and demonstrates its association with metastasis, TNM stage, and survival rates in breast cancer patients. The CASC15/miR-654-5p/MEF2D axis is identified as a key pathway in the regulation of breast cancer stemness and tumor development. These findings hold promise for the development of new therapeutic strategies for breast cancer.
Emerging evidence has demonstrated the prognostic and diagnostic potential of long noncoding RNA (lncRNA) cancer susceptibility candidate 15 (lncRNA CASC15) for the progression and tumorigenesis of human cancer. However, how CASC15 modulates the stemness of breast cancer stem cells (BCSCs) is not well understood. In this study, high expression of CASC15 in MCF-7 CSCs was reported, relative to MCF-7 cells, and this phenomenon was associated with metastatic lymph nodes, higher TNM stage, and shorter breast cancer survival rates. Further experiments revealed that CASC15 promoted the acquisition of stemness properties of breast cancer cells (BSCCs) by competing with endogenous RNA for miR-654-5p, resulting in overexpression of MEF2D in BCSCs. Overall, breast cancer stemness and tumor development are regulated via the CASC15/miR-654-5p/MEF2D axis. Accordingly, this pathway can be explored for breast cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available